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Abstract
Molecular profiling of glioblastomas has revealed the presence of key signaling hubs that 
contribute to tumor progression and acquisition of resistance. One of these main signaling 
mechanisms is the NF-κB pathway, which integrates multiple extracellular signals into 
transcriptional programs for tumor growth, invasion, and maintenance of the tumor-initiating 
population. We show here that an extracellular protein released by glioblastoma cells, fibulin-3, 
drives oncogenic NF-κB in the tumor and increases NF-κB activation in peritumoral astrocytes. 
Fibulin-3 expression correlates with a NF-κB-regulated “invasive signature” linked to poorer 
survival, being a possible tissue marker for regions of active tumor progression. Accordingly, 
fibulin-3 promotes glioblastoma invasion in a manner that requires NF-κB activation both in the 
tumor cells and their microenvironment. Mechanistically, we found that fibulin-3 activates the 
metalloprotease ADAM17 by competing with its endogenous inhibitor, TIMP3. This results in 
sustained release of soluble TNFα by ADAM17, which in turn activates TNF receptors and 
canonical NF-κB signaling. Taken together, our results underscore fibulin-3 as a novel 
extracellular signal with strong activating effect on NF-κB in malignant gliomas. Because 
fibulin-3 is produced de novo in these tumors and is absent from normal brain we propose that 
targeting the fibulin-3/NF-κB axis may provide a novel avenue to disrupt oncogenic NF-κB 
signaling in combination therapies for malignant brain tumors.
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Glioblastomas (GBMs) are the most common primary tumors in the CNS, originating from 
transformed, glial-committed, progenitor cells1. Their invasive behavior and resistance to 
chemotherapy make them one of the solid tumors with worst prognosis2, 3, resulting in a 
median survival time of approximately 15 months4. GBMs can be classified into subtypes 
with well-defined transcriptional signatures and differences in invasive behavior, 
angiogenesis, and apoptotic resistance, all of which may help tailor targeted therapies more 
accurately5–7.
GBMs are driven by a relatively small number of major signaling hubs that regulate their 
phenotype and contribute to resistance and development of malignant features5, 8. One of 
these hubs is the Nuclear Factor-kappa B (NF-κB) pathway, which responds to multiple 
extracellular signals by activating transcriptional programs that mediate inflammatory and 
immune responses9. This pathway plays a key role in GBM growth and invasion via 
enhancement of cell proliferation and apoptotic resistance, release of pro-inflammatory 
cytokines, and upregulation of metalloproteases in the tumor microenvironment10, 11. Recent 
work has also demonstrated that NF-κB regulates the conversion of the proneural subtype of 
GBMs into the more aggressive mesenchymal subtype, as well as the radio-resistance of 
these aggressive GBMs12.
Expression of NF-κB-dependent genes is driven by the active forms of NF-κB transcription 
factors (RelA/p65 and NF-κB1/p105), which are upregulated in GBM specimens and glioma 
cells compared to normal astrocytes13, 14. NF-κB upregulation typically follows the 
activation of Tumor Necrosis Factor (TNF) and IL-1 receptors in response to cytokines, but 
this pathway can also be activated by cell-intrinsic mechanisms in GBM cells, mediated by 
EGFR/Akt signaling that can bypass inhibition of TNF receptors11, 15. However, there is 
little knowledge about the regulatory mechanisms that keep sustained NF-κB activity in 
mesenchymal GBMs and their microenvironment.
A majority of GBMs secrete the glycoprotein fibulin-3, which is a component of the fibrillar 
extracellular matrix (ECM) in connective tissues but is absent from normal brain16. 
Fibulin-3 expressed in high-grade gliomas gains a novel function as autocrine/paracrine 
enhancer of Notch signaling in tumor cells and adjacent endothelial cells, leading to 
increased tumor growth, invasion and angiogenesis17, 18. We and others have shown that 
fibulin-3 also promotes resistance to temozolomide treatment and is particularly upregulated 
in mesenchymal GBMs17, 19. Because fibulin-3 appears strongly associated with the 
malignant progression of gliomas we investigated if this protein could regulate NF-κB 
signaling and the downstream pro-tumoral effects of this pathway in GBM.
We report here that fibulin-3 has a novel and remarkable driving effect on canonical NF-κB 
signaling, acting not only in the tumor but also in peritumoral glia. Fibulin-3 expression 
correlates with an increased pro-invasive NF-κB signature in experimental models and 
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clinical datasets; accordingly, this ECM protein promotes GBM invasion by ADAM17-
dependent activation of NF-κB. These results suggest that fibulin-3 is a novel oncogeni 
factor regulating the major canonical NF-κB axis in GBM.
Results
Fibulin-3 regulates NF-κB signaling in GBM cells
Overexpression of fibulin-3 cDNA in a conventional GBM cell line (U251 cells16) caused 
remarkable activation of canonical NF-κB signaling, as observed by increased 
phosphorylation of the TNFR adapter protein RIP2, IKK kinases, and the transcription 
factor p65/RelA, as well as degradation of the NF-κB inhibitor IκBα (Fig. 1A,C). In 
addition, overexpression of fibulin-3 not only increased the levels of phospho-p65 but also 
the translocation of this transcription factor to the nucleus, mimicking the stimulation of NF-
κB by TNFα (Fig. 1D,E). In contrast, when fibulin-3 expression was transiently 
downregulated in the same cells the phosphorylation of RIP2, IKK, and p65 was markedly 
decreased, indicating inhibition of NF-κB signaling (Fig. 1B,C). Strikingly, fibulin-3 
knockdown also rendered this pathway insensitive to exogenous TNFα, reducing or 
preventing activation of RIP2, IKK and p65 even when TNFα was added to the cultures. 
The dominant-negative effect of fibulin-3 knockdown on TNFα-activated NF-κB signaling 
was also observed in mesenchymal GBM stem cells (Fig. S2A–C). We further confirmed 
that fibulin-3 specifically activated canonical (i.e., IκBα-dependent) NF-κB signaling 
because its effect was prevented by transfection of a dominant-negative “super-repressor” 
form of IκBα that prevents p65 phosphorylation (Fig. S2D). Moreover, fibulin-3 
transfection did not increase the phosphorylation of RelB, a mediator of non-canonical NF-
κB signaling (Fig. S2E).
Activation of NF-κB signaling by fibulin-3 resulted in increased NF-κB transcriptional 
activity, measured with a NF-κB luciferase reporter in U251 cells (Fig. S2F) and in a second 
GBM cell line, CNS1 (Fig. 1F). These results were observed after fibulin-3 overexpression 
as well as by adding soluble, purified fibulin-3 in the CNS1 cultures (Fig 1F). We also 
replaced the luciferase reporter gene with secreted alkaline phosphatase (SEAP), which 
allowed us to collect conditioned medium from transfected cells and monitor NF-κB 
transcriptional activity over time. Stimulation with fibulin-3 or TNFα increased SEAP 
release with similar fast kinetics and did not show additive effects, suggesting that they 
shared a common mechanism (Fig. S3A). More importantly, fibulin-3 knockdown reduced 
NF-κB-dependent SEAP release and significantly diminished the effects of TNFα (Fig. 
S3B), in agreement with our dominant negative effect observed in Fig. 1B.
We next verified whether fibulin-3 had specific impact on transcriptional targets of NF-κB 
associated with cell motility and adhesion because those processes are enhanced by fibulin-3 
in GBM16. U251 cells overexpressing fibulin-3 or stimulated with soluble fibulin-3 showed 
increased expression of the pro-invasive genes tenascin-C (TNC), myosin light-chain kinase 
(MLCK) and the matrix metalloproteases MMP9 and MMP13, all of which were also 
upregulated by TNFα (Fig. 1G). Conversely, fibulin-3 knockdown caused significant 
downregulation of those genes. Together, these collective results demonstrated that fibulin-3 
is a dominant regulator of NF-κB activity in GBM cells.
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Fibulin-3 correlates with NF-κB upregulation in GBM and its microenvironment
To validate our results in vivo, we implanted invasive, fibulin-3-overexpressing, CNS1 cells 
intracranially in athymic mice. We have previously demonstrated that fibulin-3 
overexpression leads to larger, more invasive, and more vascularized CNS1 tumors16, 18. 
Here, we focused on expression of p65 as marker of NF-κB activation in the tumor core and 
surrounding peritumoral tissue.
Analysis of tissue sections from similar-sized tumors revealed a significant increase of p65 
in the core of fibulin-3-overexpressing tumors (Fig. 2A,B,G). Total expression of p65 was 
also increased in the border of these tumors but did not reach statistical significance (Fig. 
2G). However, when we focused specifically on GFAP-positive astrocytes in the tumor 
border (Fig. 2C–F) we confirmed that those cells had significant increase of p65 in fibulin-3-
overexpressing tumors (Fig. 2H). Analysis of higher magnification images revealed that the 
increased p65 significantly co-localized with nuclei both in the core and border of fibulin-3-
overexpressing tumors, indicating increased activation and nuclear localization of this NF-
κB transcription factor both in GBM and astroglial cells (Fig. 2J).
To confirm that fibulin-3 could activate NF-κB signaling in tumor-associated neural cells, 
we added purified fibulin-3 to primary cultures of brain astrocytes and brain microvascular 
endothelial cells, none of which express endogenous fibulin-3. As expected, fibulin-3 
increased phospho-p65 in both cell types (Fig. 2K). Moreover, fibulin-3 also increased the 
expression of NF-κB-dependent pro-invasive genes in astrocyte cultures (Fig. 2L) matching 
our previous result with GBM cells.
Fibulin-3 correlates with a pro-invasive NF-κB signature in GBM
Next, we studied the association of fibulin-3 (gene EFEMP1) with NF-κB transcription 
factors and NF-κB-dependent genes using transcriptomics data from the REMBRANDT and 
TCGA repositories. Fibulin-3 and its close homolog fibulin-4 (EFEMP2) showed significant 
positive correlation with canonical NF-κB transcription factors and the pro-invasive genes 
that we had assayed in Fig. 1G, except MMP13, which was expressed at very low levels in 
GBMs (Fig. S4A–B). Cluster analysis of those genes using TCGA microarray data revealed 
two well-defined patient populations with high and low gene co-expression (Fig. 3A) and 
significantly different survival curves (Fig. 3B).
Further analysis of fibulin-3 and NF-κB p65 (gene RELA) expression showed that the 
average co-expression of both genes was highest in the mesenchymal subtype of GBMs 
(Fig. 3C), which were the predominant subtype in the patient population with poorer 
survival. Moreover, analysis of intra-tumoral expression from an independent dataset (IVY 
Glioblastoma Atlas Project) confirmed the significant correlation of both genes (Fig. 3D) 
and their preferential co-expression in peri-necrotic pseudopalisade areas, which typically 
contain a “escaping” population of migratory glioma cells20.
Because the NF-κB pathway regulates the expression of hundreds of genes, we next asked if 
fibulin-3 expression had preferential correlation with specific transcriptional programs or 
acted as an indiscriminate NF-κB activator. To answer this we used publically available 
surveys to compile a list of 348 genes directly regulated by NF-κB (Suppl. Table S3) and 
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correlated their expression against fibulin-3 using TCGA microarray data (Suppl. Table S3). 
We then chose two groups of 100 genes with the highest and lowest correlation against 
fibulin-3 and used Ingenuity Pathway Analysis to identify relevant pathways and cellular 
functions represented in each group (Suppl. Table S4). The analysis suggested that the top 
NF-κB-dependent cellular functions highly correlated with fibulin-3 are those involved in 
cell motility or invasion, matching the known function of fibulin-3 in GBM. On the other 
hand, NF-κB-regulated functions poorly correlated with fibulin-3 included cell proliferation 
and signaling in the nervous and immune systems (Fig. 3E). We further confirmed that genes 
identified as poorly correlated with fibulin-3 (e.g., cytokines IL-2, IL-12B, and IL-17) 
effectively did not change expression after fibulin-3 overexpression or knockdown in U251 
cells (Fig. S4C).
The pro-invasive effects of fibulin-3 require NF-κB signaling
Fibulin-3 predominantly regulates cell adhesion and invasion in GBM16 and maintains the 
viability of the GBM stem cell population, even though it does not increase GBM cell 
proliferation17. Therefore, we next investigated if these phenotypic effects was mediated 
NF-κB as predicted from our in silico data.
We first measured the effect of fibulin-3 on cell adhesion and observed that fibulin-3-
overexpressing U251 cells had increased adhesion to fibronectin-coated substrates, as 
expected (Fig. 4A). However, this effect was completely abolished when the cells were co-
transfected with p65 siRNA or with the NF-κB “super-repressor” form of IκB. Next, we 
measured cell invasion using highly invasive CNS1 cells seeded on cultured brain slices, 
which provide an accurate ex vivo model for GBM dispersion in neural tissue21 (U251 cells 
are poorly invasive in vivo and do not disperse in cultured brain tissue). Fibulin-3-
overexpressing CNS1 cells dispersed much further than control cells (Fig. 4B) but this effect 
was abolished by co-transfection of p65 siRNA (Fig. 4C) or by treating the cultures with the 
NF-κB inhibitor CAPE22 (Fig. 4D). A more specific NF-kB inhibitor, BAY-11-7082, was 
also assayed but caused unavoidable toxicity in the cells and cultured brain tissue (Fig. 
S5A). Together, results from Figs. 4A–D confirmed that fibulin-3 drives a NF-κB-
dependent, pro-invasive mechanism in GBM cells. In contrast, although fibulin-3 
knockdown reduced GBM stem cell viability as previously described17, this effect was 
independently rescued by TNFα (Fig. S5B), suggesting that fibulin-3 effects on GBM 
viability were probably not dependent on, or correlated with, NF-κB signaling, as predicted 
from Fig. 3E.
Finally, we evaluated if the pro-invasive effect of fibulin-3 was tumor cell-intrinsic or could 
also involve NF-κB regulation in peritumoral brain tissue as suggested from our results in 
vivo (Fig. 2). We repeated our brain slice invasion assays using neonatal brain tissue from 
NF-κB-deficient mice lacking both TNFR1 and p65 expression23. Remarkably, CNS1 cells 
were unable to invade through NF-κB-deficient brain slices and the pro-invasive effect of 
fibulin-3 was completely suppressed (Fig. 4F). Taken together, our results suggest that the 
leading function of fibulin-3 as pro-invasive factor in GBMs is mediated by its ability to 
drive NF-κB-dependent “pro-invasion programs” both in tumor cells and their 
microenvironment.
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NF-κB regulation by fibulin-3 involves control of CYLD expression and TACE activity
We finally investigated the mechanism of NF-κB activation by fibulin-3, focusing on 
possible mechanisms triggered by this ECM protein at the cell membrane level.
Fibulin-3 can compete with Notch inhibitors to directly activate Notch signaling in GBM, 
increasing the expression of Notch-regulated genes such as the transcription factors 
Hes-117, 18. Work in T-cell leukemia has shown that Hes-1 represses the expression of the 
de-ubiquitinase CYLD24, which is a NF-κB inhibitor that acts by preventing degradation of 
IκB25. Therefore, we reasoned that fibulin-3 stimulation of Notch could downregulate 
CYLD and indirectly activate NF-κB.
To test this hypothesis, we first confirmed that CYLD knockdown was sufficient to increase 
phosphorylation of p65 in U251 cells (Fig. 5A). Then, as predicted, we observed that 
fibulin-3 overexpression downregulated CYLD mRNA whereas fibulin-3 knockdown caused 
the opposite effect (Fig. 5B). Surprisingly, blockade of Notch signaling with the gamma-
secretase inhibitor DAPT17 did not prevent the downregulation of CYLD (Fig. 5C) and the 
activation of NF-κB p65 (Fig. 5D) by fibulin-3. These results suggested that fibulin-3 may 
regulate Notch and NF-κB mechanisms independently in GBM. Even if CYLD-
downregulation underlies, in part, the activation of NF-κB by fibulin-3, this mechanism does 
not depend on Notch signaling as postulated in other cancers. This prompted to investigate 
which other “nodes” could be regulated by fibulin-3 to result in joint but independent 
regulation of Notch and NF-κB pathways.
An indirect mechanism by which fibulin-3 can activate Notch in GBM involves increased 
activity of the metalloproteases ADAM10 and ADAM1718, which cleave and activates 
Notch receptors26. These enzymes are also known as TNFα convertases (TACE) because 
one of their major functions is the cleavage of membrane-bound pro-TNFα to release 
soluble TNFα, which in turn activates TNF receptors and NF-κB signaling27. Therefore, we 
investigated if regulation of ADAM10/17 could be a mechanism by which fibulin-3 
regulated NF-κB signaling in parallel and independent manner from Notch signaling.
Overexpression of fibulin-3 in U251 cells significantly increased the expression of 
ADAM17 mRNA, but not ADAM10 (Fig. 6A), as well as TACE enzymatic activity (Fig. 
6B). TACE activity was also increased when purified fibulin-3 was added to lysates of GBM 
cells (Fig. 6B), suggesting that fibulin-3 directly regulated enzymatic activity of ADAM17 
in addition to its expression. Accordingly, fibulin-3 stimulation of GBM cells increased the 
cleavage of membrane-bound pro-TNFα and the release of soluble TNFα to the culture 
medium (Fig. 6C). Moreover, inhibition of TACE activity with the small-molecule inhibitor 
TAPI-2 was sufficient to abolish the enhancing effect of fibulin-3 on p65 phosphorylation 
(Fig. 6D), suggesting that this was a key mechanism by which fibulin-3 regulated the NF-κB 
pathway.
Because ADAM17 seemed to be the TACE enzyme responsive to fibulin-3, we next 
investigated if these proteins interacted directly to activate NF-κB. We could not detect a 
significant association between fibulin-3 and ADAM17 by co-immunoprecipitation (Fig. 
S6), suggesting that fibulin-3 probably regulated other mediator protein(s) that interact with 
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ADAM17. A well-known inhibitor of ADAM17 is the Tissue Inhibitor of Metalloproteases 
TIMP328, which also binds to fibulin-329 and can be “sequestered” by fibulin-3 in GBM18. 
Accordingly, the effect of fibulin-3 on NF-κB was inhibited by TIMP3 in a concentration-
dependent manner (Fig. 6E), suggesting that fibulin-3 competes with TIMP3 to activate 
ADAM17. Finally, we used the TNFα small-molecule inhibitor C87, which does not prevent 
cleavage of pro-TNFα but inhibits the binding of released TNFα to TNF receptors and 
reduces NF-κB activation. Treatment of fibulin-3-overexpressing cells with C87 did not 
prevent the increase of soluble TNFα but strongly inhibited NF-κB activation (Fig. 6F). 
Together, these results strongly suggest a model in which fibulin-3 prevents TIMP3 
inhibition of ADAM17, resulting in sustained release of TNFα that activates TNF receptors 
and therefore canonical NF-κB signaling (Fig. 6G).
Discussion
Dysregulated, constitutive activation of NF-κB signaling is a central mediator of 
inflammatory and anti-immune processes that correlate with tumor progression30, 31. In 
GBMs, sustained NF-κB activity is necessary for the maintenance of the tumor-initiating 
cell population32, 33 and for tumor progression towards a more aggressive phenotype12 that 
involves enhanced invasion34 and neo-angiogenesis35. NF-κB activation also occurs in 
tumor-associated astrocytes36 and microglia37–39, which contribute to tumor progression. 
Because NF-κB components are rarely mutated in adult GBMs40 this suggests that the 
pathway becomes constitutively activated by alterations in key regulatory mechanisms.
Our results suggest that fibulin-3 is a novel soluble signal that drives NF-κB signaling in 
GBMs and their microenvironment. Fibulin-3 is one of seven members of the fibulin family 
that are found in the basal lamina of blood vessels and the ECM of connective tissues41. 
These glycoproteins have been largely regarded as structural components necessary for the 
mechanical integrity of tissue42, 43 but their overexpression in cancer has revealed novel 
roles as soluble signals that facilitate cell adhesion, growth, and motility44.
The upregulation of fibulin-3 in cancer was first described in high-grade gliomas16 and 
pancreatic carcinomas45, after which this protein was identified as a pro-tumoral factor in 
several types of metastatic solid tumors46–51. Mechanistically, fibulin-3 has been shown to 
activate the EGFR/Akt axis in pancreatic cancer cells52 but this mechanism was not 
observed in GBM cells17, 53. Instead, we and others demonstrated that fibulin-3 directly 
activates the Notch pathway in GBM cells17, 19 and tumor-associated endothelial cells18, 
resulting in increased tumor invasion, angiogenesis, and chemoresistance. The current 
knowledge of fibulin-3 in GBMs underscores this ECM protein not only as a marker of 
tumor aggressiveness but more importantly as a promoter of malignant progression17, 19.
Here, we have demonstrated that the effects of fibulin-3 in GBM correlate with, and depend 
on, activation of canonical NF-κB. Fibulin-3 expression matches NF-κB upregulation in 
experimental models and clinical datasets, with preferential co-expression in mesenchymal 
GBMs and in tumor regions populated by invasive cells, all of which makes fibulin-3 a 
possible marker for regions of active tumor progression. Moreover, our in silico and in vitro 
data indicate that fibulin-3 promotes invasion in GBM by concerted NF-κB activation both 
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in tumor cells and astroglia (Figs. 2 and 4), driving a NF-κB-dependent pro-invasive 
signature that includes genes for cell adhesion (tenascin-C), motility (MLCK) and ECM 
remodeling (metalloproteases). Overall, these results suggest that fibulin-3 may be among 
the key signals that stimulate and sustain NF-κB to favor the malignant progression of 
GBMs.
The molecular interactions of fibulin-3 with NF-κB regulatory proteins remain to be fully 
elucidated but our results already indicate that fibulin-3 likely activates NF-κB by preventing 
TIMP3 inhibition of ADAM17, therefore increasing the activity of this enzyme. This, in 
turn, increases the availability of soluble TNFα to bind TNF receptors and activate canonical 
NF-κB. This finding is of particular significance because ADAM17 is a “master protease” 
on the cell surface that regulates multiple signaling pathways54, 55 for tumor growth, 
invasion, angiogenesis, and immune escape56–59. Regulation of ADAM17 activity by 
fibulin-3 explains the ability of this ECM protein to activate both Notch (by cleavage of 
Notch-1 receptor) and NF-κB (by shedding of TNFα) in parallel and independent fashion, 
and suggests that there may be more pathways modulated by fibulin-3 in a similar manner. 
We acknowledge that some molecular effects of fibulin-3 may not be explained by ADAM17 
regulation, such as the dominant inhibition of NF-κB signaling after fibulin-3 knockdown 
(Fig. 1). It is possible that fibulin-3 downregulation increases CYLD that in turn inhibits NF-
κB signaling, but the mechanisms by which fibulin-3 regulates CYLD at the transcriptional 
level is yet unknown. Further work is needed to identify cell-surface mechanisms tonically 
regulated by fibulin-3 and affected by the loss of this protein.
NF-κB remains a challenging target for molecular therapies because of the multitude of 
cellular mechanisms controlled by this pathway, which raises concern for the adverse effects 
that may result from total NF-κB inhibition31, 32. New research has focused on inhibiting 
key NF-κB activating signals, thus disrupting NF-κB transcriptional programs with high-
specificity and fewer off-target effects. The oncogenic effect of fibulin-3 on NF-κB is likely 
a GBM-specific function because fibulin-3 is neither soluble in normal tissues nor expressed 
in the brain16, 60. Therefore, specific targeting of fibulin-3/NF-κB interactions could inhibit 
tumor progression with potentially limited side effects. We suggest that targeting a 
fibulin-3/NF-κB axis may provide a novel avenue to improve combination therapies for 
GBM.
Materials and Methods
Cell cultures
GBM cell lines, GBM stem cells, primary mouse astrocytes, and human brain microvascular 
endothelial cells were cultured following standard methods, as described16–18. Human U251 
cells were chosen for manipulation with fibulin-3 cDNA or siRNA because they have 
moderate endogenous levels of fibulin-3 among glioma lines16. Rat CNS1 cells were used to 
study invasion mechanisms because U251 cells are poorly invasive through brain tissue. All 
cells were authenticated using the “Cell Check” service (IDEXX-Research Animal 
Diagnostic Laboratory, Columbia MO). All supplements were removed from the cultures 
during in vitro tests requiring addition of fibulin-3 or TNFα.
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DNA and RNA constructs
Fibulin-3 cDNA was cloned in the plasmid pcDNA3.1(+) (Life Technologies, Carlsbad CA) 
for transient transfections and subcloned into the lentiviral vector pCDH-EF1-copGFP 
(System Biosciences, Mountain View CA) for constitutive expression in GBM cells16. 
siRNA oligonucleotides against fibulin-3, p65, and CYLD (Qiagen, Valencia CA) were 
transfected at 100 pmol/5×105 cells and validated at the mRNA and protein levels (17 and 
Fig. S1). Cells were used in assays or processed 48 h after transfections. All transfections 
were performed with Lipofectamine-2000 (Life Technologies) following the manufacturer’s 
recommendations.
The NF-κB reporter plasmid pGL4.32/luc2P/NF-κB-RE was from Promega (Madison WI). 
The SEAP reporter plasmid was generated by removing the luciferase sequence in plasmid 
pGL4.32 and inserting the sequence of secreted alkaline phosphatase from plasmid 
pSEAP2-Control (Clontech, Mountain View CA). A plasmid carrying the cDNA for the 
degradation-resistant, super-repressor form of IκBα61 (pCMX-IκBα-M) was purchased 
from Addgene (Cambridge, MA).
Biochemical assays
Transfected cells were lysed and processed for semiquantitative RT-PCR or Western blotting 
using standard protocols16 (antibodies and primers are listed in Suppl. Tables S-I and S-II). 
Cultures were treated overnight with the gamma-secretase inhibitor DAPT (25 μM, Tocris 
Bioscience, Bristol UK) or the TACE inhibitor TAPI-2 (1 μM, Cayman Chemical, Ann 
Arbor MI). Cells were also treated with TNFα (10 ng/ml, Peprotech, Rocky Hill NJ), 
fibulin-3 (300 ng/ml, Origene, Rockville MD), or the TNFα inhibitor C87 (10 μM, Tocris) 
for 1 to 24 h before collection. For reporter assays a plasmid carrying Renilla luciferase was 
co-transfected as loading control.
To measure TACE activity, cells were lysed in 50 mM Tricine buffer (pH 7.5) containing 100 
mM NaCl, 10 mM CaCl2, 1 mM ZnCl2 and 0.1% Triton X-100. Clarified lysates (50 μg total 
protein) were incubated with a fluorogenic ADAM10/17 substrate peptide (TACE substrate 
III) as described18.
Cell-based assays
To quantify nuclear translocation of p65, cells were treated with fibulin-3 or TNFα and 
processed for immunocytochemistry using an antibody against total p65. Nuclear 
translocation was quantified by co-localization of p65 with nuclear DAPI staining. For cell 
adhesion assays, U251 cells were dissociated and seeded (25,000 cells/well) on fibronectin-
coated wells (5 μg/ml) for 1h. Adhered cells were fixed, stained with crystal violet and 
quantified as described16. For cell invasion assays, CNS1 cells were transfected with 
combinations of cDNAs and siRNAs and allowed to form tumorspheres for 48 before 
seeding on brain slices; cell dispersion was quantified by imaging methods as described16. 
The NF-κB inhibitors caffeic acid methyl ester (CAPE, 20 μM, Tocris) or BAY-11-7082 
(0.5-5 μM Calbiochem, Billerica MA) were added to the slice culture medium for the 
duration of the experiments. To assess the role of microenvironmental NF-κB, spheroids 
were seeded on brain slices from neonatal NF-κB-deficient mice (TNFR1−/− p65−/−, 
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selected from a heterozygous colony)23 provided by Dr. Denis Guttridge (The Ohio State 
University). To quantify GBM stem cell viability, dissociated cells were transfected with 
control or fibulin-3 siRNAs and plated in 96-well plates at a density of 2,000 cells/well. 
Cultures were spiked with TNFα (10 ng/ml) every other day after plating. Cell viability was 
assessed by ATP production using the CellTiter-Glo kit (Promega)17.
Animal procedures
All animal experiments were approved by the Animal Care and Use Committees at the 
Brigham and Women’s Hospital and SUNY Upstate Medical University. GFP-expressing 
CNS1 cells (5 × 104 cells in 2 μL) were implanted in the striatum of athymic mice as 
described16, 17. Brains were collected 20 days after tumor implantation and processed for 
cryo-sectioning at 20 μm. Sections were fixed in 4% paraformaldehyde and processed for 
immunohistochemistry to detect p65 and GFAP. Tumor boundaries were identified by GFP 
expression and high cellular density (nuclear DAPI staining). Sections were imaged using a 
confocal microscope Zeiss LSM710.
Clinical datasets and pathway analysis
GBM microarray data was obtained from REMBRANDT (Affymetrix HG-U133 v2.0+, 
N=214) and TCGA (Affymetrix Human Exon 1.0 ST, N=202, Affymetrix, HG-U133A, 
N=198 and Agilent G4502A, N=198) databases. Criteria from Ceccarelli et al.62 were used 
to exclude GBMs harboring 1p/19q co-deletion. Standard scores (Z scores) were calculated 
for fibulin-3 (EFEMP1), fibulin-4 (EFEMP2), NF-κB transcription factors (RELA, RELB, 
NFKB1, NFKB2) and pro-invasive genes (TNC, MLCK, MMP9, MMP13); expression of 
fibulin-3 was then correlated with each gene (Pearson’s correlation) across the different 
microarray platforms. Optimal heatmap clustering was calculated using the R’s package 
NBClust. Molecular subtypes of GBM were identified in the TCGA dataset using profiles 
provided by the GBM Bio-Discovery Portal (http://gbm-biodp.nci.nih.gov)63. RNAseq data 
(Z scores) for intratumoral expression of EFEMP1 and RELA in histologically-defined, 
microdissected regions from 10 GBM specimens (total N=122 samples) was obtained from 
the IVY Glioblastoma Atlas Project repository (http://glioblastoma.alleninstitute.org)
To perform correlation analysis between fibulin-3 and NF-κB-regulated genes we first 
reviewed publically available surveys of predicted and tested NF-κB targets (http://
bioinfo.lifl.fr/NF-KB/ and http://www.bu.edu/nf-kb/gene-resources/target-genes)64, 65 to 
compile a list of 348 genes directly regulated by NF-κB. We next used TCGA GBM 
microarray data to correlate EFEMP1 with each NF-κB-regulated gene, followed by 
Bonferroni correction of p values for multiple comparisons. Correlations were filtered for 
significance (adjusted p<0.05) and sorted by Pearson’s Rho value to select 100 genes with 
the highest correlation with fibulin-3 (highest absolute Rho values) and 100 genes with the 
lowest correlation (Rho closest to zero) (Suppl. Table S-III). Each group of genes was 
separately analyzed using Ingenuity Pathway Analysis (Qiagen) to identify the most 
represented networks of signaling pathways and cellular functions. Those networks were 
scored based on how many genes from the original 100-gene list (“focus molecules”) were 
found in each network (Suppl. Table S-IV). This yielded two lists of ranked cellular 
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functions containing NF-κB-regulated genes; one list for genes with highest correlation with 
fibulin-3 and another for genes with lowest correlation with fibulin-3.
Statistics
Experiments in vitro were repeated in triplicate with 3–5 independent replicates (8 replicates 
for invasion assays). Animals studies were performed in duplicate with N=5 per 
experimental condition (to detect differences at least twice as large as the S.D. of the groups, 
at power 80% and p<0.05). Blinding and randomization for animal studies followed the 
ARRIVE guidelines for animal research66. Grubb’s test was used to detect outlier results; all 
differences were deemed significant at p<0.05.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Fibulin-3 activates canonical NF-κB signaling
A) Fibulin-3 overexpression in U251 cells increased phosphorylation (p-) of NF-κB 
components (RIP2, IKK αβ, and p65) and degradation of IκBα. B) Conversely, fibulin-3 
downregulation with siRNA prevented activation of NF-κB signaling even in presence of 
TNFα (10 ng/ml × 1 h). C) Quantification of Western blotting results from (A) and (B). The 
optical density (O.D.) for each phospho-protein band was normalized to its own total protein 
(or actin for IκB); bars represent fold-change (in log scale) in O.D. for each condition 
compared against their control (control transfections were given arbitrary O.D. value of 1). 
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D) Treatment of U251 cells with fibulin-3 (2 h) or TNFα (30 min) increased the 
translocation of p65 to the nucleus. E) Quantification of nuclear p65 in cells from (D), co-
localized with nuclear DAPI stain (*** p<0.001, one-way ANOVA). F) CNS1 cells carrying 
a NF-κB-dependent reporter were cultured with no treatments (vehicle), transfected with 
control or fibulin-3 cDNAs (control cells and fib-3 OE cells), or treated with purified 
fibulin-3 (300 ng/ml × 4h). Stimulation with transfected or exogenous fibulin-3 resulted in 
reporter activation (** p<0.01; ***p<0.001, one-way ANOVA). Similar results were 
observed in U251 cells (Fig. S2F). G) U251 cells were treated with TNFα, soluble purified 
fibulin-3 (sol. fib-3), or transfected with fibulin-3 cDNA or siRNA (or their controls), and 
processed for qRT-PCR. Fibulin-3 levels regulated the expression of the NF-κB-dependent 
genes TNC, MLCK, MMP9 and MMP13. Results were compared by one-way ANOVA for 
each gene (* p<0.05; ** p<0.01; # p<0.001).
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Figure 2. Fibulin-3 overexpression activates NF-κB in the tumor and its microenvironment
A–B) Representative low-magnification images of CNS1-derived intracranial tumors stained 
for total p65 (red) and cell nuclei (DAPI, light blue). The dashed line represents the 
boundary between the tumor core (defined by density of nuclei and GFP-expressing tumor 
cells, channel not shown) and border. Notice the considerable p65 staining beyond the 
boundary of fibulin-3-overexpressing tumors (arrows). C-D) Representative images as in 
(A–B) revealing intra- and peri-tumoral GFAP staining (green); p65 staining is shown in 
grayscale to avoid obscuring GFAP within the tumor core. E–F) Higher magnification 
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images of the squares highlighted in panels (C) and (D). G–H) Quantification of p65-
positive and GFAP-positive areas within (core) and around (border) the tumor mass. P65 
staining was normalized to total tumor area and GFAP/P65-positive areas were normalized 
to total GFAP area. Results showed an increase in p65 expression in the tumor mass and in 
surrounding astroglia of fibulin-3-overexpressing tumors. J) Quantification of p65-positive 
nuclei in the tumor core and border, relative to total nuclei per area unit. Results show 
increased nuclear localization of p65 in fibulin-3-overexpressing tumors. Results in (G)–(J) 
were compared by repeated measures 2-way ANOVA with Sidak’s correction for multiple 
comparisons; * p<0.05; ** p<0.01; *** p<0.001. K) Soluble fibulin-3 (300 ng/ml × 1h) 
increased p65 phosphorylation in cultures of astrocytes and human brain microvascular 
endothelial cells (HBMECs). L) Soluble fibulin-3 also increased the expression of NF-κB-
regulated genes in cultured astrocytes (*** p<0.01 by Student’s t-test for each gene).
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Figure 3. Fibulin-3 correlates with a NF-κB-regulated invasive signature
A) Gene expression clustering in GBMs using normalized TCGA data for EFEMP1, 
EFEMP2, NF-κB transcription factors, and fibulin-3-correlated pro-invasive genes tested in 
Fig. 1. Unsupervised cluster analysis revealed two major patient populations (red and blue 
lines) characterized by high and low co-expression of these genes. B) Kaplan-Meier analysis 
of those two populations showed significantly poorer survival in patients with higher co-
expression of fibulin-3 and NF-κB-associated genes (p=0.014 by log-rank test). C) Co-
expression of fibulin-3 (EFEMP1) and p65 (RELA) was higher in the mesenchymal and 
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classical subtypes of GBMs compared to neural and proneural subtypes. Bars represent the 
standard error in Z-score for each subtype and the size of the circles represent the number of 
cases for subtype. D) Intratumoral expression of EFEMP1 and RELA from a set of 10 
specimens with 5 histologically-defined regions: leading edge (LE); infiltrating tumor (IT); 
core tumor (CT); pseudopalisading cells around necrosis (PAN); and microvascular 
proliferation region (MVP). Numbers in parentheses are averaged Z scores for EFEMP1 and 
RELA expression. Results suggested preferential co-expression of both genes in perinecrotic 
areas of the tumor. E) NF-κB-regulated genes that were highly or poorly correlated with 
fibulin-3 (Table S-III) were aggregated into functional networks (Table S-IV). Networks 
were scored (red/green bars) based on the number of NF-κB-regulated genes found in each 
network (# Focus Molecules). NF-κB-regulated genes highly correlated with fibulin-3 were 
predominantly associated with cellular movement and cell-cell interactions, while genes not 
correlated with fibulin-3 were involved in cell growth and proliferation and immune 
responses.
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Figure 4. Fibulin-3 requires NF-κB for cell adhesion and invasion
A) U251 cells were tested for adhesion to fibronectin-coated wells. Fibulin-3 cDNA 
expression increased cell adhesion but this effect was abolished by co-expression of p65 
siRNA or IκBα super-repressor (IKBα rep) cDNA, both of which inhibited NF-κB 
activation (adhesion different from control at **p<0.01, ***p<0.001; one-way ANOVA). B) 
Representative images of control (ctrl) and fibulin-3-overexpressing (fib-3) CNS1 
tumorspheres seeded and dispersing on mouse brain slices. C-D) The pro-invasive effect of 
fibulin-3 was highly attenuated or abolished when cells were transfected with p65 siRNA 
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(C) or when NF-κB was inhibited with CAPE (20 μM) (D). E) CNS1 tumorspheres were 
also seeded on brain slices from NF-κB deficient mice (NFκB-def; TNFR1−/− RelA/p65−/−) 
or their wild-type littermates. NF-κB deficiency in brain tissue abolished cell invasion and 
the pro-invasive effect of fibulin-3. Results in (C) to (E) were analyzed by two-way ANOVA 
for repeated measures; asterisks indicate differences between fibulin-3-expressing cells and 
their respective control (** p<0.01; *** p<0.001).
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Figure 5. Fibulin-3 regulates the NFκB inhibitor CYLD in a Notch-independent manner
A) Knockdown of the enzyme CYLD (CYLD siRNA) in U251MG cells increased the 
phosphorylation of p65. B) Overexpression or knockdown of fibulin-3 in U251MG cells 
resulted in the opposite down- or up-regulation of CYLD mRNA. C) Overexpression of 
fibulin-3 continued to repress CYLD expression even when the cells were treated with the 
Notch inhibitor DAPT (25 μM). D) Increased phosphorylation of p65 by fibulin-3 was also 
resistant to Notch inhibition, suggesting that fibulin-3 regulates NF-κB signaling by a 
mechanism that does not require Notch activation. Results in (B) and (C): *** p<0.001 by 
one-way ANOVA.
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Figure 6. Fibulin-3 stimulates ADAM17 to produce TNFα and activate NF-κB
A) Fibulin-3 overexpression (OE) increased ADAM17 mRNA (*** p<0.001, Student’s t-
test) but not ADAM10 mRNA in U251 cells. B) Lysates from fibulin-3-overexpressing cells 
or co-incubated with purified fibulin-3 for 6h also showed increased ADAM17/TACE 
enzymatic activity (*** p<0.001, one-way ANOVA). C) Fibulin-3 overexpression increased 
the cleavage of membrane-bound pro-TNFα and release of soluble TNFα, which can 
activate NF-κB. D) The enhancing effect of fibulin-3 on p65 phosphorylation (in U251 cells) 
was blocked by the ADAM17 inhibitor TAPI-2 (1 μM). E) Activation of NF-κB by fibulin-3 
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was also inhibited in a concentration-dependent manner by the ADAM17 endogenous 
inhibitor, TIMP3. The bar graph shows quantitative results from triplicate experiments 
(significant differences from control cells at *** p<0.001; one-way ANOVA). F) The small-
molecule inhibitor C87 did not prevent activation of ADAM17 and release of soluble TNFα 
by fibulin-3, but blocked TNFα and downstream activation of NF-κB. G) Proposed 
mechanism of action of fibulin-3 to activate NF-κB via sustained activation of ADAM17 
and accumulation of soluble TNFα.
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